{"id":"NCT02941926","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC","officialTitle":"COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-30","primaryCompletion":"2019-11-08","completion":"2022-11-09","firstPosted":"2016-10-21","resultsPosted":"2022-05-09","lastUpdate":"2023-10-24"},"enrollment":3246,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Ribociclib","otherNames":["LEE011"]},{"type":"DRUG","name":"Letrozole","otherNames":[]},{"type":"DRUG","name":"Goserelin","otherNames":[]},{"type":"DRUG","name":"Leuprolide","otherNames":[]}],"arms":[{"label":"Ribociclib + letrozole+goserelin/leuprolide","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and pre/postmenopausal women with HR+HER2- advanced breast cancer and no prior hormonal treatment for advanced disease..","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) During Treatment With Ribociclib + Letrozole in the Core Phase","timeFrame":"From start of treatment up to 30 days after last treatment (for participants who did not enter to the Extension phase) or up to last treatment in the Core phase (for participants who entered the Extension phase), assessed up to approximately 33 months.","effectByArm":[{"arm":"Ribociclib + Letrozole + Goserelin/Leuprolide","deltaMin":3203,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":3},"locations":{"siteCount":495,"countries":["United States","Argentina","Austria","Belgium","Bulgaria","Canada","Chile","Czechia","Denmark","Finland","France","Greece","Hong Kong","Hungary","India","Israel","Italy","Jordan","Lebanon","Malaysia","Mexico","Netherlands","Norway","Oman","Panama","Philippines","Poland","Portugal","Russia","Saudi Arabia","Singapore","Slovakia","Slovenia","Spain","Sweden","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["36267663","36206609","36152144","35212906","34414532"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":702,"n":3246},"commonTop":["Neutropenia","Nausea","Fatigue","Arthralgia","Diarrhoea"]}}